Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil
Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
To establish efficacy of Idalopirdine as adjunctive therapy to donepezil for symptomatic
treatment of patients with mild-to-moderate Alzheimer's disease (AD).